SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Gurgle HE, White K, McAdam-Marx C

Vascular Health and Risk Management 2016, 12:239-249

Published Date: 4 June 2016